Gilead Sciences, an American biopharmaceutical company, agreed to invest $66m in Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles platform. Gilead is looking to bolster its protein therapeutics pipeline, so the early-stage collaboration with Tentarix will fit right in, according to Flavius Martin, M.D., executive vice president of research at the pharma.